Mepsevii Approved for Rare Enzyme Disorder

WEDNESDAY, Nov. 15, 2017 — Mepsevii (vestronidase alfa-vjbk) has been approved by the U.S. Food and Drug Administration to treat a rare, genetic disorder called mucopolysaccharidosis type VII, sometimes called Sly syndrome.
Affecting fewer than 150…
Source: Topamax